CN116491655A - 益生菌益生元组合物在制备提高肠道益生菌定植的食品中的应用 - Google Patents
益生菌益生元组合物在制备提高肠道益生菌定植的食品中的应用 Download PDFInfo
- Publication number
- CN116491655A CN116491655A CN202310440525.6A CN202310440525A CN116491655A CN 116491655 A CN116491655 A CN 116491655A CN 202310440525 A CN202310440525 A CN 202310440525A CN 116491655 A CN116491655 A CN 116491655A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- probiotic
- colonization
- lactobacillus
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 84
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 84
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 19
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 14
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 20
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 20
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 8
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 8
- 241000186660 Lactobacillus Species 0.000 claims abstract description 7
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 4
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 14
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 14
- 241001608472 Bifidobacterium longum Species 0.000 claims description 10
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 10
- 235000013350 formula milk Nutrition 0.000 claims description 10
- 240000000696 Lactobacillus helveticus R0052 Species 0.000 claims description 8
- 235000005877 Lactobacillus helveticus R0052 Nutrition 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 7
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 241000186012 Bifidobacterium breve Species 0.000 claims description 5
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 claims description 5
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 claims description 2
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 102220066049 rs146636139 Human genes 0.000 claims description 2
- 241000901051 Bifidobacterium animalis subsp. animalis Species 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 abstract description 26
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 26
- 235000020256 human milk Nutrition 0.000 abstract description 23
- 210000004251 human milk Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 11
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 11
- 229940107187 fructooligosaccharide Drugs 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000007613 environmental effect Effects 0.000 description 8
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101100248157 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) rfbP gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 101150078797 luxS gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了益生菌益生元组合物在制备提高肠道益生菌定植的药物或食品中的应用,所述肠道益生菌选自乳杆菌和/或双歧杆菌。本发明的益生菌益生元组合物通过两歧双歧杆菌R0071与2’‑岩藻糖基乳糖组合能够促进大多数母乳低聚糖不代谢菌株的定植,且对母乳低聚糖代谢菌株R0033的定植没有抑制作用,进一步说明两歧双歧杆菌R0071与2’‑岩藻糖基乳糖组合可通过促进母乳低聚糖不代谢菌株生长进而促进其定植。
Description
技术领域
本发明属于医药食品技术领域,具体涉及益生菌益生元组合物在制备提高肠道益生菌定植的药物或食品中的应用。
背景技术
益生菌是一种活的微生物且在摄取适当的量下有助于宿主(人体或其他生物)健康。目前,中国对于婴幼儿可食用菌株采取审批制的形式,共有14株菌株被纳入名单中。虽然这些菌株在体外实验中均已被证实对肠道细胞具有一定的粘附能力,但是在临床中大部分菌株定植时间仍然较短,导致临床结果不佳(Candela et al.2005;Capurso 2019;Gopalet al.2001;Greene and Klaenhammer 1994;Jungersen et al.2014;Olivares etal.2006;Toscano et al.2014;Xiao et al.2021)。益生菌定植并不是只是简单得粘附上皮细胞,在粘附之后益生菌会受胃肠道恶劣的环境挑战,如酸性环境、抗生素、致病菌、耐盐、液体的冲刷等。虽然大部分商业化益生菌菌株均进行了大部分的环境耐受力评估,但是在应对抗生素环境压力下,处于安全考虑,我们并不能使用耐药性菌株,因此开发一种安全的方式来提高益生菌环境耐受力及其定植是必要的。
生物被膜(Biofilm)作为一种新的策略被大量的学者关注,它指的是细菌粘附在某一界面上并且自身分泌胞外基质形成一个封闭空间,内部的细菌相互附着,成为一种细菌群体共同生存的形式,该基质主要有胞外多糖(exopolysaccharides,EPS)、蛋白质、胞外DNA(Extracellular DNA,eDNA)等。大量的研究表明生物被膜具有物理稳定性、表面可感应性、内部环境分布梯度性与多样性等特点,能够使生物被膜内细菌(如益生菌)低于不利环境条件,如抗生素(Salas-Jara et al.2016)。同时,研究表明与生物被膜形成相关基因(如luxS、rfbP等)的敲除菌株,其在体内定植量显著降低,这表明益生菌的生物被膜形成能力是其定植的关键因素之一(Xiao et al.2021)。然而,目前大部分商业菌株并没有进行生物被膜能力的测定,此外少量菌株做了相关的评估,但实验模拟的环境采用普通的碳源(葡萄糖)不符合肠道环境条件,以益生元来模拟胃肠道的碳源更为合理。
目前,已被批准使用的益生菌种类繁多,而不同菌株的益生元代谢能力不尽相同,最大的差异在于母乳低聚糖(human milk oligosaccharides,HMO)的代谢能力,仅有少数的益生菌菌株能够代谢,大部分无法利用,因此大部分商业上的益生菌菌株与HMO组合使用时无法发挥HMO的最大作用。为促进HMO健康功效以及大部分无法代谢HMO益生菌的定植量,本发明将通过探索不同益生元下益生菌的相互作用,开发一种益生菌益生元组合HMObiotics应用于胃肠道中益生菌的定植。
本发明的难点在于菌株之间存在多种相互作用关系,如协同作用、拮抗作用、共生、竞争等,因此多菌株益生菌产品往往存在菌株之间相互拮抗的潜在风险。过去多篇研究表明,某些菌株的组合在某些功能上并没有发挥协同作用。Lynne V.McFarland通过对临床研究进行meta分析发现,与单一使用相比,鼠李糖乳杆菌GG与混合其他菌株(动物双歧杆菌乳亚种Bb-12或HN019,或长双歧杆菌长亚种BB536)联合使用对预防坏死性结肠炎的预防效果更差。相反,与单一菌株相比,鼠李糖乳杆菌GG动物与动物双歧杆菌乳亚种Bb-12组合对幽门螺旋杆菌根除率则显著提高。这表明同一益生菌组合在不同的功能方向上,并不能总是维持协同增效的作用,甚至有可能起到拮抗作用。此外,菌株之间的相互作用关系也会随着环境条件的变化而发生变化。目前,对于益生菌相互作用关系研究仍非常有限,少数研究去使用同一菌株来探究两者之间功效上的差异。因此,本发明筛选了不同的益生元与益生菌的组合,开发一种益生菌益生元组合HMObiotics协同增强在胃肠道中益生菌定植的应用。
发明内容
为了弥补现有技术的不足,本发明的目的在于提供一种益生菌益生元组合物HMObiotics在提高肠道益生菌定植的应用。为了实现本发明的目的,拟采用如下技术方案:
本发明提供了益生菌益生元组合物在在提高肠道益生菌定植的应用,其特征在于所述益生菌益生元组合物中的益生菌为两歧双歧杆菌R0071,所述益生菌益生元组合物中的益生元为2’-岩藻糖基乳糖,所述肠道益生菌为乳杆菌和/或双歧杆菌。
根据权利要求1所述的应用,所述乳杆菌或者双歧杆菌选自动物双歧杆菌乳亚种或动物双歧杆菌Bb-12(Bifidobacterium animalis subsp.Lactis或Bifidobacteriumanimalis Bb-12)、长双歧杆菌婴儿亚种或婴儿双歧杆菌R0033(Bifidobacterium longumsubsp.infantis或Bifidobacterium infantis R0033)、动物双歧杆菌乳亚种或乳双歧杆菌HN019和Bi-07(Bifidobacterium animalis subsp.lactis或Lactobacillus lactisHN019,Bifidobacterium animalis subsp.lactis或Lactobacillus lactis Bi-07)、短双歧杆菌M16V(Bifidobacterium breve M16V),瑞士乳杆菌R0052(Lactobacillushelveticus R0052)、鼠李糖乳杆菌LGG或GG(Lactobacillus rhamnosus LGG或GG,Lactobacillus rhamnosus HN001)、长双歧杆菌长亚种BB536(Bifidobacterium longumsubsp.longum BB536)、嗜酸性乳杆菌NCFM(Lactobacillus acidophilus NCFM)中的至少一种、两种的组合。
在本发明的一个优选实施方式中,所述益生菌的浓度为1×106-1×1014CFU/100g,较佳地为1×108-1×1014CFU/100g。
在本发明的一个优选实施方式中,所述食品为配方奶粉或营养组合物。
在本发明的一个优选实施方式中,所述的配方奶粉或营养组合物是婴幼儿配方奶粉或婴幼儿用营养组合物产品。
在本发明的一个优选实施方式中,所述的婴幼儿奶粉或营养组合物中2’-岩藻糖基乳糖的含量10mg/100g~10×103mg/100g,较佳地为10×101~10×103mg/100g;所述两歧双歧杆菌R0071的含量为1×106-1×1014CFU/100g,较佳地为1×108-1×1014CFU/100g。
本发明的优点为:本发明的益生菌益生元组合物通过两歧双歧杆菌R0071与2’-岩藻糖基乳糖组合能够促进大多数母乳低聚糖不代谢菌株的定植,且对母乳低聚糖代谢菌株R0033的定植没有抑制作用,进一步说明两歧双歧杆菌R0071与2’-岩藻糖基乳糖组合可通过促进母乳低聚糖不代谢菌株生长进而促进其定植。
附图说明
图1不同益生菌菌株的低聚糖代谢能力;
图2两歧双歧杆菌R0071与2’-FL组合对肠道益生菌定植量的影响。
注:星号表示与测试菌株单菌株培养相比具有显著性差异(P<0.05)
图3两歧双歧杆菌R0071与FOS组合对肠道益生菌定植量的影响。
注:星号表示与测试菌株单菌株培养相比具有显著性差异(P<0.05)
图4两歧双歧杆菌R0071与葡萄糖组合对肠道益生菌定植量的影响。
注:星号表示与测试菌株单菌株培养相比具有显著性差异(P<0.05)
具体实施方式
为了进一步理解本发明,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
如无特殊说明,本发明实施例中所涉及的试剂均为市售产品,均可以通过商业渠道购买获得。
实施例1:
1实验方法
1.1培养基配制
含有不同碳源的cfMRS肉汤培养基配方(1L):10g碳源,10g蛋白胨,5g酵母提取物,1mL吐温80,2g K2HPO4,5g CH3COONa·3H2O,2g柠檬酸三铵,200mg MgSO4·7H2O,50mgMnSO4·4H2O,0.5g半胱氨酸盐,1L超纯水,pH调节至6.2-6.5。其中碳源包括,2’-岩藻糖基乳糖(2’-FL),6-唾液酸乳糖(6’-SL),乳糖-N-新四糖(LNnT),低聚果糖(FOS),低聚半乳糖(GOS),葡萄糖(Gluose)。
1.2实验菌株及其培养活化
本研究共使用4株乳杆菌和8株双歧杆菌,其中乳杆菌包括嗜酸性乳杆菌NCFM,瑞士乳杆菌R0052,鼠李糖乳杆菌GG,鼠李糖乳杆菌HN019;双歧杆菌包括长双岐杆菌婴儿亚种R0033,长双岐杆菌婴儿亚种M63,长双岐杆菌长亚种BB536,动物双歧杆菌乳亚种BI-07,动物双歧杆菌乳亚种HN019,动物双歧杆菌乳亚种Bb-12,两歧双歧杆菌R0071,短双歧杆菌M-16V。如下表1:
表1益生菌菌株名单
通过平板划线或涂布的方式,将上述益生菌菌株冻存液或菌粉分别接种在MRS琼脂培养基中,于37℃厌氧培养48h后,取得富含单菌落的MRS琼脂平板。使用无菌枪头或接种环从MRS琼脂平板中挑取各菌株单菌落,接种在MRS肉汤培养于37℃厌氧隔夜培养,得到活化的益生菌菌液并用于后续的实验,其中菌液浓度通过Live/DeadTM试剂盒(ThermoFisher)进行测定。
1.3益生菌低聚糖代谢能力测定
各菌株隔夜培养菌液(方法1.2)使用无碳源的cfMRS肉汤培养基进行稀释,并以106CFU/mL分别接种至含有不同低聚糖(2’-FL,6’-SL,LNnT,FOS,GOS)的cfMRS肉汤培养基中,以无碳源的cfMRS培养作为阴性对照,以含有葡萄糖的cfMRS肉汤培养作为阳性对照。在厌氧培养箱于37℃培养72h后,在波长为595nm进行OD的测定。
1.4益生菌相互作用共培养实验
基于1.3的实验结果,选取3个菌株进行共培养实验,分别是瑞士乳杆菌R0052,长双歧杆菌婴儿亚种R0033以及两歧双歧杆菌R0071。各菌株隔夜培养菌液(方法1.2)均以106CFU/mL分别接种至含2’-FL的cfMRS肉汤培养基中,共有3组实验组为单一菌株培养,3组实验组为两两菌株共培养(R0052+R0033,R0052+R0071,R0033+R0071)。无碳源cfMRS肉汤培养基接种单一菌株作为阴性对照组。接种后的样品均置于37℃厌氧培养20h后,取适量样品使用细菌DNA小提试剂盒(DNB361-03B,Mabio)进行DNA提取,使用NanoDrop 2000(ThermoFisher)对DNA样品进行质检,合格的样品将通过qPCR对样品中各菌株细胞数进行定量分析。
qPCR的定量分析采用外标法,首先绘制阈值循环数Cq值与DNA拷贝数的标准曲线,通过NanoDrop 2000对各益生菌单一菌株的DNA样品进行浓度测定,随后使用双蒸水进行10倍稀释,配置梯度拷贝数浓度(102到109)的DNA样品,配置qPCR扩增体系(如下表2),在qPCR仪按照设定的程序(如下表3)使用各菌株特异性引物(如下表4)测定各样品的Cq值,方可得到Cq值与DNA拷贝数的标准曲线,其中DNA拷贝数通过以下公式计算对应的:
对已知10倍梯度浓度的各益生菌菌液(105-107CFU/mL)进行DNA提取,通过qPCR测定各浓度下的Cq值,并根据标准曲线获取对应的DNA拷贝数,随后计算各菌株活菌数与DNA拷贝数总数比值,三个浓度梯度下的比值取均值作为转换系数(a)。最终样品中各菌株的细胞数通过以下公式进行定量分析:
测试菌株细胞数(cell number/mL)=测试菌株拷贝数(copies/μL)×转换系数a
表2 qPCR扩增体系配置
表3 qPCR扩增程序
表4各菌种的特异性正反链引物
1.5益生菌定植量测定
基于1.3和1.4的实验结果,选取5个菌株进行实验,来探究两歧双歧杆菌R0071对益生菌定植量的影响,涉及的菌株分别是瑞士乳杆菌R0052,长双歧杆菌婴儿亚种R0033,两歧双歧杆菌R0071,长双歧杆菌长亚种BB536,以及动物双歧杆菌乳亚种HN019。该实验将在三种不同的碳源下进行,包括2’-FL,FOS和葡萄糖,探究不同碳源与两歧双歧杆菌R0071组合对益生菌定植量的影响。各隔夜培养菌液(方法1.2)以106CFU/mL分别接种至含2’-FL的cfMRS肉汤培养基中。对于单一菌株组别,各菌株稀释液与含2’-FL的cfMRS肉汤培养基以1:1的比例混合;对于两菌株组别,两歧双歧杆菌稀释液以1:1的比例与其余实验菌株进行混合。随后取适量(600μL)的混合液加入48孔微孔板中,并将微孔板置于37℃静置厌氧培养24h。为除去游离的细胞(未粘附的细胞),使用合适的PBS温和地清洗微孔两次;随后使用无菌枪头刮掉孔板底部的生物被膜,并用600μL的PBS来重悬浮。根据核酸染色试剂盒(Thermo)的说明书,对重悬浮菌液进行染色,避光孵育15min后,使用流式细胞仪进行定量荧光测定,最终以总菌数来表征定植量。将2’-FL更换成FOS或葡萄糖后重复上述实验,以探究不同碳源与两歧双歧杆菌R0071组合对益生菌定植量的影响。
2实验结果
2.1不同益生菌菌株的低聚糖代谢能力
如图1,在2’-FL中只有R00033,M63和R0071能够较好地生长;在6’-SL中只有M63和R0071能够较好生长;在LNnT中只有R0033,M63,R0071和M-16V可以生长;而R0071,GG以及HN001均无法在FOS上生长;此外,GG以及HN001在GOS中生长也有限。综上,R0071对所有测试的母乳低聚糖代谢能力较强,将作为HMO分解者的代表;R0033对部分测试的母乳低聚糖代谢具有代谢能力,将作为部分HMO分解者的代表;而R0052对测试的母乳低聚糖没有分解代谢能力,将作为无法利用HMO的代表,三者将进行后续的相互作用实验探究各菌株之间的相互作用关系。
2.2益生菌之间的协同增长
表5-7为在2’-FL中不同益生菌两两共培养后各菌株的总菌数。与2.1的结果一致,R0052单一菌株在2’-FL为碳源的培养中总菌数没有显著增长,说明R0052无法代谢2’-FL进行生长,而R0033和R0071单一培养的总菌数均显著增加,说明这两菌株均能代谢2’-FL进行生长。此外,在两菌株共培养的实验中,两歧双歧杆菌R0071均能够提高长双歧杆菌婴儿亚种R0033和瑞士乳杆菌R0052的细胞数,该结果表明了R0071可能通过释放胞外酶分解2’-FL为岩藻糖和乳糖,从而为R0033和R0052提供营养组分,促进其生长增值。
表5在2’-FL中R0033与R0071单独培养或共培养后各菌株的细胞数
注:上标星号表示与同行的单一菌株培养相比具有显著性差异(P<0.05)
表6在2’-FL中R0052与R0071单独培养或共培养后各菌株的细胞数
注:上标星号表示与同行的单一菌株培养相比具有显著性差异(P<0.05)
表7在2’-FL中R0052与R0033单独培养或共培养后各菌株的细胞数
注:上标星号表示与同行的单一菌株培养相比具有显著性差异(P<0.05)
2.3两歧双歧杆菌与不同碳源组合对肠道益生菌定植量的影响
如图2,结果表明以2’-FL为碳源,与单一生物被膜相比,R0071分别与9种不同益生菌菌株形成混合生物被膜中益生菌的总菌数均显著增加,包括R0052、GG、HN001、NCFM、BB536、HN019、BI-07、Bb12、M-16V,说明R0071与2’-FL组合能够协同促进不同肠道益生菌的定植。而R0071与R0033的混合生物被膜中益生菌总菌数与R0033单一菌株生物被膜的总菌数相当,说明R0071与2’-FL组合并不会影响R0033的定植。
如图3,结果表明以FOS为碳源,与单一生物被膜相比,R0071分别与5种不同益生菌菌株形成混合生物被膜中益生菌的总菌数均显著增加,包括R0052、BB536、GG、NCFM、BI-07;而R0071与3种不同菌株益生菌的混合生物被膜中益生菌总菌数比单一菌株生物被膜的总菌数显著降低,包括R0033、HN019、M-16V。这表明R0071与FOS的组合会抑制部分菌株的定植。
如图4,结果表明以葡萄糖为碳源,与单一生物被膜相比,R0071分别与3种不同益生菌菌株形成混合生物被膜中益生菌的总菌数均显著增加,包括R0052、R0033以及BI-07;而R0071与4种不同菌株益生菌的混合生物被膜中益生菌总菌数比单一菌株生物被膜的总菌数显著降低,包括BB536、HN019、NCFM、M-16V,这表明R0071与葡萄糖的组合会抑制部分菌株的定植。
综上结果,R0071与FOS组合效果欠佳,促进定植效果不理想,可能的原因是R0071无法代谢FOS,因此没有起到协同增效的作用。R0071与葡萄糖组合效果欠佳,可能由于葡萄糖属于广谱性的碳源,菌株相互之间产生竞争,从而没有起到协同增效的作用。而R0071与2’-FL组合效果最佳,对所有测试菌株的定植均没有抑制作用,且能促进大多数(9/10)测试菌株的定植。
结合2.1,2.2以及2.3的结果表明,由于大多数益生菌无法利用母乳低聚糖,因此在正常母乳喂养的婴幼儿肠道中益生菌难以定植。其中母乳低聚糖(2’-FL)代谢菌株有两株,只有R0071能够促进其他益生菌菌株(R0052)在母乳低聚糖中生长,说明R0071与母乳低聚糖组合下能够协同促进母乳低聚糖不代谢菌株的生长代谢。同时R0071与2’-FL组合能够促进大多数母乳低聚糖不代谢菌株的定植,且对母乳低聚糖代谢菌株R0033的定植没有抑制作用,进一步说明R0071与2’-FL组合可能通过促进母乳低聚糖不代谢菌株生长进而促进其定植。
以上描述了本发明优选实施方式,然其并非用以限定本发明。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。
Claims (6)
1.益生菌益生元组合物在制备提高肠道益生菌定植的药物或食品中的应用,其特征在于所述益生菌益生元组合物中的益生菌为双岐双歧杆菌R0071,所述益生菌益生元组合物中的益生元为2-岩藻糖基乳糖,所述肠道益生菌选自乳杆菌和/或双歧杆菌。
2.根据权利要求1所述的应用,所述乳杆菌或者双歧杆菌选自动物双歧杆菌乳亚种或动物双歧杆菌Bb-12(Bifidobacterium animalis subsp.Lactis或Bifidobacteriumanimalis Bb-12)、长双歧杆菌婴儿亚种或婴儿双歧杆菌R0033(Bifidobacterium longumsubsp.infantis或Bifidobacteriuminfantis R0033)、动物双歧杆菌乳亚种或乳双歧杆菌HN019和Bi-07(Bifidobacterium animalis subsp.lactis或Lactobacillus lactisHN019,Bifidobacterium animalis subsp.lactis或Lactobacillus lactis Bi-07)、短双歧杆菌M16V(Bifidobacterium breve M16V),瑞士乳杆菌R0052(Lactobacillushelveticus R0052)、鼠李糖乳杆菌LGG或GG(Lactobacillus rhamnosus LGG或GG,Lactobacillus rhamnosus HN001)、长双歧杆菌长亚种BB536(Bifidobacterium longumsubsp.Longum BB536)、嗜酸性乳杆菌NCFM(Lactobacillus acidophilus NCFM)中的至少一种、两种、三种或者多种的组合。
3.根据权利要求1所述的应用,所述益生菌的浓度为1×106-1×1014CFU/100g。
4.根据权利要求1所述的应用,所述食品为配方奶粉或营养组合物。
5.根据权利要求4所述的应用,所述的配方奶粉或营养组合物是婴幼儿配方奶粉或婴幼儿用营养组合物产品。
6.根据权利要求5所述的应用,所述的婴幼儿奶粉中2’-岩藻糖基乳糖的含量10mg/100g~10×103mg/100g;所述两歧双歧杆菌R0071的含量为1×106-1×1014CFU/100g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310440525.6A CN116491655A (zh) | 2023-04-21 | 2023-04-21 | 益生菌益生元组合物在制备提高肠道益生菌定植的食品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310440525.6A CN116491655A (zh) | 2023-04-21 | 2023-04-21 | 益生菌益生元组合物在制备提高肠道益生菌定植的食品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116491655A true CN116491655A (zh) | 2023-07-28 |
Family
ID=87317690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310440525.6A Pending CN116491655A (zh) | 2023-04-21 | 2023-04-21 | 益生菌益生元组合物在制备提高肠道益生菌定植的食品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116491655A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170216373A1 (en) * | 2009-01-12 | 2017-08-03 | Pfizer Italia S.R.L. | Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin |
CN111935995A (zh) * | 2018-03-29 | 2020-11-13 | 森永乳业株式会社 | 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉 |
CN112189850A (zh) * | 2020-09-17 | 2021-01-08 | 合生元(广州)健康产品有限公司 | 益生元在促进胃肠道中益生菌存活的应用 |
CN113080462A (zh) * | 2021-05-21 | 2021-07-09 | 郑州大学第二附属医院 | 用于婴幼儿促生肠道微生态环境的微生物制剂 |
CN114369563A (zh) * | 2021-12-30 | 2022-04-19 | 海普诺凯营养品有限公司 | 一种短双歧杆菌活性促进剂 |
-
2023
- 2023-04-21 CN CN202310440525.6A patent/CN116491655A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170216373A1 (en) * | 2009-01-12 | 2017-08-03 | Pfizer Italia S.R.L. | Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin |
CN111935995A (zh) * | 2018-03-29 | 2020-11-13 | 森永乳业株式会社 | 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉 |
CN112189850A (zh) * | 2020-09-17 | 2021-01-08 | 合生元(广州)健康产品有限公司 | 益生元在促进胃肠道中益生菌存活的应用 |
CN113080462A (zh) * | 2021-05-21 | 2021-07-09 | 郑州大学第二附属医院 | 用于婴幼儿促生肠道微生态环境的微生物制剂 |
CN114369563A (zh) * | 2021-12-30 | 2022-04-19 | 海普诺凯营养品有限公司 | 一种短双歧杆菌活性促进剂 |
Non-Patent Citations (2)
Title |
---|
SADAKI ASAKUMA 等: "Physiology of Consumption of Human Milk Oligosaccharides by Infant Gut-associated Bifidobacteria", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 40, pages 34583, XP055172931, DOI: 10.1074/jbc.M111.248138 * |
徐克成 等: "乳与乳制品的生理功能特性", 上海科技教育出版社, pages: 664 - 305 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prabhurajeshwar et al. | Evaluation of antimicrobial properties and their substances against pathogenic bacteria in-vitro by probiotic Lactobacilli strains isolated from commercial yoghurt | |
Ashraf et al. | Selective and differential enumerations of Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium spp. in yoghurt—A review | |
Gagnon et al. | In vitro inhibition of Escherichia coli O157: H7 by bifidobacterial strains of human origin | |
Dunne et al. | In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings | |
Bao et al. | Screening of potential probiotic properties of Lactobacillus fermentum isolated from traditional dairy products | |
WO2021114658A1 (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
Romani Vestman et al. | Characterization and in vitro properties of oral lactobacilli in breastfed infants | |
US20080299099A1 (en) | Strain composition of the lactobacillus genus and the application of strain composition of the lactobacillus genus | |
CN115039885B (zh) | 一种具有抑制奇异变形杆菌生长作用的副干酪乳杆菌及其益生菌组合物、发酵液和应用 | |
CN113913322B (zh) | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 | |
TWI785815B (zh) | 用於促進益生菌生長的方法 | |
Liu et al. | Screening of bifidobacteria with acquired tolerance to human gastrointestinal tract | |
Hadadji et al. | Identification of cultivable Bifidobacterium species isolated from breast-fed infants feces in West-Algeria | |
CN112195123B (zh) | 一种植物乳杆菌及其制剂和应用 | |
CN113817622B (zh) | 一株具有减轻致癌物对人体细胞基因毒性作用的长双歧杆菌及其应用 | |
Figueroa-González et al. | Antimicrobial effect of Lactobacillus casei strain Shirota co-cultivated with Escherichia coli UAM0403 | |
Damaceno et al. | Isolation and identification of potential probiotic bacteria from human milk | |
CN109715181B (zh) | 细菌 | |
Mahmoudi et al. | Identification and physiological properties of Bifidobactérium strains isolated from different origin | |
Gao et al. | Screening of potential probiotics with anti-Helicobacter pylori activity from infant feces through principal component analysis | |
Arboleya et al. | Production of immune response mediators by HT-29 intestinal cell-lines in the presence of Bifidobacterium-treated infant microbiota | |
Murphy | In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract | |
WO2011118764A1 (ja) | 生菌数の測定方法及び培地 | |
KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
Ram et al. | Optimization of culture conditions of probiotic bifidobacteria for maximal adhesion to hexadecane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40089248 Country of ref document: HK |